An emerging immunotherapy treatment, chimeric antigen receptor (CAR) T-cell therapy can be very effective in treating patients with B-cell malignancies. However, knowledge gaps exist over the role of CAR T-cell therapy in the management of these patients. In an effort to close these gaps, i3 Health provided an NCPD-approved online strategy session titled Understanding and Optimizing CAR T-Cell Therapy for Patients With B-Cell Malignancies.
A total of 539 participants completed this activity, including 501 nurses, 25 nurse practitioners, and 3 physicians. A baseline assessment revealed that only 53% of participants knew T cells are drawn from a patient's blood for CAR T-cell therapy, 43.2% knew axicabtagene ciloleucel efficacy, 75.2% knew how to effectively manage neurotoxicity, 35.3% knew the efficacy of tisagenlecleucel, and 46.4% knew how to properly assess cytokine release syndrome. After completing the activity, those numbers improved to 94%, 91%, 93%, 86%, and 94%, respectively.
As a result of completing the educational content, 71% of participants felt more likely to educate patients receiving CAR T-cell therapy about cytokine release syndrome and 43% of participants planned on educating patients receiving CAR T-cell therapy about neurologic toxicities. Another 32% of participants planned on performing neurologic assessments in patients receiving CAR T-cell therapy. Approximately 75% of participants planned to share this educational activity with their colleagues.
These results show the effectiveness of the activity on participants' knowledge surrounding the CAR T-cell manufacturing process, efficacy of CAR T-cell therapies, and management of CAR T-cell therapy-related adverse events.
i3 Health (2020). Understanding and Optimizing CAR T-Cell Therapy for Patients With B-Cell Malignancies: activity outcomes summary report. Data on file.
Image Courtesy of Nephron. Licensed under CC BY-SA 3.0